Tingting Zhang, Shu-ye Yang, Lili Lin, Shuo Wang, D. Xia, Donghe Chen, Guo-lin Wang, Kui Zhao, X. Su
OBJECTIVE Fluorine-18-2-(3-{1-carboxy-5-[(6-18F-flfluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid (18F-DCFPyL), a novel positron emission tomography/computed tomography (PET/CT) radiotracer that binds to the prostate specific membrane antigen (PSMA), is increasingly used for biochemically recurrent prostate cancer diagnostics. However, the 18F-DCFPyL characteristics of suspected prostate cancer (SPCa) have been even more rarely described. Herein, in this retrospective study, we describe the clinical impact of 18F-DCFPyL PET/CT imaging in SPCa. SUBJECTS AND METHODS We retrospectively evaluated the data of 56 SPCa patients who had undergone 18F-DCFPyL PET/CT studies. These patients were done for primary diagnosis/staging. Positron emission tomography/CT images were analyzed both qualitatively and quantitatively (maximum standardized uptake value (SUVmax) and maximum SUV normalized by lean body mass (SULmax)). Histopathologic diagnosis was taken as reference standard. The optimal cut-off of 18F-DCFPyL was determined using receiver operating characteristic curve (ROC). RESULTS All the patients were confirmed by histopathological examination via prostatectomy or prostate biopsy. Fluorine-18-DCFPyL PET/CT showed higher radiotracer uptake in prostate cancer than that in non-prostate cancer. When SUVmax 5.0 and SULmax 4.0 were cut-off points for determining prostate cancer, the sensitivity of 18F-DCFPyL was 90%, specificity was 100%, and accuracy was 91.2%. Furthermore, there were highly significant positive correlations between SUVmax, SULmax and serum PSA. On comparison of areas under the curve, no significant difference was seen between SUVmax and SULmax in the sensitivity and specificity of 18F-DCFPyL PET/CT for PCa identification. However, delayed PET/CT did not improved accuracy in the term of uncertain PCa in the initial standard imaging. As for lymph node staging, the negative predictive value of 18F-DCFPyL PET/CT was 100%. CONCLUSION Fluorine-18-DCFPyL PET/CT is a promising imaging modality for initial diagnosis and preoperative N staging in SPCa.
{"title":"Role of 18F-DCFPyL PET/CT in patients with suspected prostate cancer.","authors":"Tingting Zhang, Shu-ye Yang, Lili Lin, Shuo Wang, D. Xia, Donghe Chen, Guo-lin Wang, Kui Zhao, X. Su","doi":"10.1967/s002449912431","DOIUrl":"https://doi.org/10.1967/s002449912431","url":null,"abstract":"OBJECTIVE Fluorine-18-2-(3-{1-carboxy-5-[(6-18F-flfluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid (18F-DCFPyL), a novel positron emission tomography/computed tomography (PET/CT) radiotracer that binds to the prostate specific membrane antigen (PSMA), is increasingly used for biochemically recurrent prostate cancer diagnostics. However, the 18F-DCFPyL characteristics of suspected prostate cancer (SPCa) have been even more rarely described. Herein, in this retrospective study, we describe the clinical impact of 18F-DCFPyL PET/CT imaging in SPCa. SUBJECTS AND METHODS We retrospectively evaluated the data of 56 SPCa patients who had undergone 18F-DCFPyL PET/CT studies. These patients were done for primary diagnosis/staging. Positron emission tomography/CT images were analyzed both qualitatively and quantitatively (maximum standardized uptake value (SUVmax) and maximum SUV normalized by lean body mass (SULmax)). Histopathologic diagnosis was taken as reference standard. The optimal cut-off of 18F-DCFPyL was determined using receiver operating characteristic curve (ROC). RESULTS All the patients were confirmed by histopathological examination via prostatectomy or prostate biopsy. Fluorine-18-DCFPyL PET/CT showed higher radiotracer uptake in prostate cancer than that in non-prostate cancer. When SUVmax 5.0 and SULmax 4.0 were cut-off points for determining prostate cancer, the sensitivity of 18F-DCFPyL was 90%, specificity was 100%, and accuracy was 91.2%. Furthermore, there were highly significant positive correlations between SUVmax, SULmax and serum PSA. On comparison of areas under the curve, no significant difference was seen between SUVmax and SULmax in the sensitivity and specificity of 18F-DCFPyL PET/CT for PCa identification. However, delayed PET/CT did not improved accuracy in the term of uncertain PCa in the initial standard imaging. As for lymph node staging, the negative predictive value of 18F-DCFPyL PET/CT was 100%. CONCLUSION Fluorine-18-DCFPyL PET/CT is a promising imaging modality for initial diagnosis and preoperative N staging in SPCa.","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2022-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44537806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pseudomyogenic hemangioendothelioma (PMH) presenting with right ventricle and pancreas involvement is very rare. Herein, we reported a 46-year-old man who presented multiple subcutaneous nodules throughout the body for eight months.Fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) revealed multiplehypermetabolic lesions including in the soft tissues, right ventricle and pancreas. Fine needle aspiration of subcutaneous nodule revealed a PMH.
{"title":"18F-FDG PET/CT imaging of pseudomyogenic hemangioendothelioma presenting as multiple nodules with right ventricle and pancreas involvement.","authors":"Liu-zhen Xiao, Wenjie Zhang, Lin Li","doi":"10.1967/s002449912440","DOIUrl":"https://doi.org/10.1967/s002449912440","url":null,"abstract":"Pseudomyogenic hemangioendothelioma (PMH) presenting with right ventricle and pancreas involvement is very rare. Herein, we reported a 46-year-old man who presented multiple subcutaneous nodules throughout the body for eight months.Fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) revealed multiplehypermetabolic lesions including in the soft tissues, right ventricle and pancreas. Fine needle aspiration of subcutaneous nodule revealed a PMH.","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2022-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46430874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
OBJECTIVE To analyze the incidence and associated factors of hypothyroidism after radioiodine treatment for hyperthyroidism during a 13-year follow-up period. SUBJECTS AND METHODS This was a retrospective study of consecutive patients with hyperthyroidism who were treated using a single dose of radioactive iodine (RAI) with a calculated dose regimen from 07/2005 to 12/2012. Univariate and multivariate Cox regression models were used to examine the factors that are associated with the occurrence of hypothyroidism after RAI therapy. Kaplan-Meier analysis was used for confirming associations between these models. RESULTS A total of 182 patients were included during a 7.5-year median follow-up (range: 6-13 years). They were 36.4±11.1 years. The mean radioactive iodine dosage was 308.2±104.3 (range: 129.5-740.0) MBq. The rates of euthyroidism, early hypothyroidism, improvement, and ineffective treatment at 6 months were 48.4%, 37.9%, 8.8%, and 4.9%, respectively. The cumulative incidence of hypothyroidism in all patients with hyperthyroidism was 45.6% at 1 year, 48.9% at 5 years, and 52.3% at 10 years. Thyroid weight >46g (HR=0.643, 95%CI: 0.422-0.981, P=0.040) and a course of disease of 0.5-3 years (HR=0.592, 95%CI: 0.358-0.981, P=0.042) were identified as independent factors associated with an increased risk of hypothyroidism after radioactive iodine therapy. CONCLUSION Radioactive iodine treatment with a calculated dose has a high cure rate for hyperthyroidism and has a low annual increase of hypothyroidism. Hypothyroidism after radioactive iodine treatment is more likely to occur in patients with small thyroid and a short disease course.
{"title":"Development of hypothyroidism over 13 years of follow-up of patients with hyperthyroidism after radioiodine therapy.","authors":"Jian Fang Li, Liangjun Xie, Luping Qin, Qi-chang Wan, Jin Ping Li, Qingquan Wu, Mu-Hua Cheng","doi":"10.1967/s002449912433","DOIUrl":"https://doi.org/10.1967/s002449912433","url":null,"abstract":"OBJECTIVE\u0000To analyze the incidence and associated factors of hypothyroidism after radioiodine treatment for hyperthyroidism during a 13-year follow-up period.\u0000\u0000\u0000SUBJECTS AND METHODS\u0000This was a retrospective study of consecutive patients with hyperthyroidism who were treated using a single dose of radioactive iodine (RAI) with a calculated dose regimen from 07/2005 to 12/2012. Univariate and multivariate Cox regression models were used to examine the factors that are associated with the occurrence of hypothyroidism after RAI therapy. Kaplan-Meier analysis was used for confirming associations between these models.\u0000\u0000\u0000RESULTS\u0000A total of 182 patients were included during a 7.5-year median follow-up (range: 6-13 years). They were 36.4±11.1 years. The mean radioactive iodine dosage was 308.2±104.3 (range: 129.5-740.0) MBq. The rates of euthyroidism, early hypothyroidism, improvement, and ineffective treatment at 6 months were 48.4%, 37.9%, 8.8%, and 4.9%, respectively. The cumulative incidence of hypothyroidism in all patients with hyperthyroidism was 45.6% at 1 year, 48.9% at 5 years, and 52.3% at 10 years. Thyroid weight >46g (HR=0.643, 95%CI: 0.422-0.981, P=0.040) and a course of disease of 0.5-3 years (HR=0.592, 95%CI: 0.358-0.981, P=0.042) were identified as independent factors associated with an increased risk of hypothyroidism after radioactive iodine therapy.\u0000\u0000\u0000CONCLUSION\u0000Radioactive iodine treatment with a calculated dose has a high cure rate for hyperthyroidism and has a low annual increase of hypothyroidism. Hypothyroidism after radioactive iodine treatment is more likely to occur in patients with small thyroid and a short disease course.","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2022-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45844880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
E. Pasini, E. Panagiotidis, L. Zoglopitou, T. Kalathas, A. Makridou, V. Chatzipavlidou
Prostate cancer (PCa) is one of the most common malignancies and cause of cancer death in men. Prostate-specific antigen (PSA) is the most used biomarker in the detection of early PCa. Lately, scientists have been using prostate-specific membrane antigen (PSMA), a glycol-protein that is over-expressed in PCa cells in positron emission tomography/ computed tomography (PET/CT) scans to detect PCa. Gallium-68-PSMA radiotracers, such as 68Ga-PSMA-11, 68Ga-PSMA-617 and 68Ga-PSMA I&T, were firstly introduced in 2011 and fluorine-18-PSMA based radiotracers followed with 18F-PSMA-1007,N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]- 4-18F-fluorobenzyl-L-cysteine(18F-DCFBC) and 2-(3-(1-carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl)-ureido)- pentanedioic acid (18F-DCFPyL), also known as PYLARIFY, being the most used and showed superior results compared to conventional imaging techniques. Differences depending on half-life, clearance and normal organ uptake are being detected through research to determine which of the radiotracers, is the most suitable for each patient. Two of them, 68Ga-PSMA-11 and PLYRIFY, have already been approved by the Food and Drug Administration (FDA). The future of hybrid imaging for PCa is very promising if we consider the advantages of PSMA radiotracers compared to non-PSMA radioligands.
{"title":"Comparative study of the most commonly-used radiopharmaceuticals for PSMA prostate PET/CT imaging.","authors":"E. Pasini, E. Panagiotidis, L. Zoglopitou, T. Kalathas, A. Makridou, V. Chatzipavlidou","doi":"10.1967/s002449912437","DOIUrl":"https://doi.org/10.1967/s002449912437","url":null,"abstract":"Prostate cancer (PCa) is one of the most common malignancies and cause of cancer death in men. Prostate-specific antigen (PSA) is the most used biomarker in the detection of early PCa. Lately, scientists have been using prostate-specific membrane antigen (PSMA), a glycol-protein that is over-expressed in PCa cells in positron emission tomography/ computed tomography (PET/CT) scans to detect PCa. Gallium-68-PSMA radiotracers, such as 68Ga-PSMA-11, 68Ga-PSMA-617 and 68Ga-PSMA I&T, were firstly introduced in 2011 and fluorine-18-PSMA based radiotracers followed with 18F-PSMA-1007,N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]- 4-18F-fluorobenzyl-L-cysteine(18F-DCFBC) and 2-(3-(1-carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl)-ureido)- pentanedioic acid (18F-DCFPyL), also known as PYLARIFY, being the most used and showed superior results compared to conventional imaging techniques. Differences depending on half-life, clearance and normal organ uptake are being detected through research to determine which of the radiotracers, is the most suitable for each patient. Two of them, 68Ga-PSMA-11 and PLYRIFY, have already been approved by the Food and Drug Administration (FDA). The future of hybrid imaging for PCa is very promising if we consider the advantages of PSMA radiotracers compared to non-PSMA radioligands.","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2022-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48694128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
J. Petrović, S. Beatovic, D. Šobić-Šaranović, S. Odalović, M. Stojiljković, I. Grozdić-Milojević, Miloš Veljković, Darko Jovanović, V. Artiko
OBJECTIVE Positron emission tomography/computed tomography using fluorine-18 fluoro-deoxyglucose (18F-FDG PET/CT) is not routinely used for diagnosis of testicular carcinoma. Unlike CT which cannot confirm with certainty the nature of the lesions, especially in post-therapy setting, 18F-FDG PET/CT detects active disease by showing increased glucose metabolism within the lesions. AIM Determination of 18F-FDG PET/CT usefulness in detection of seminoma, therapy response evaluation and comparison to CT findings and tumor marker levels. MATERIAL AND METHODS Eighty-two men (age 39.8±10.1) after orchiectomy and histopathological confirmation of seminoma were included in this study. Indications for 18F-FDG PET/CT were initial staging, restaging after chemo/radiotherapy with positive/uncertain CT, suspected recurrence on CT, elevated tumor markers. All patients had clinical follow-up of up to 8 years (median 33.5) after the first 18F-FDG PET/CT examination. Degree of metabolic activity was analyzed visually and semi-quantitatively using maximum standardized uptake value(SUVmax). RESULTS Fluorine-18-FDG PET/CT was true positive in 36 patients (43.9%) with average SUVmax of 7.9±4.8.Recurrence was mostly found in retroperitoneal lymph nodes and distant metastases in lungs, bones, liver. Six findings were false positive and 3 false negative. Sensitivity, specificity, accuracy of 18F-FDG PET/CT were 92.3%, 86.0%, 89.0% and of CT 60.8%, 66.6%, 63.4%. Pearson Chi-square test showed statistically significant difference between the results of 18F-FDG PET/CT and CT (P=0.016). Significant correlation was found between positive 18F-FDG PET/CT findings and levels of LDH (P=0.043), while non-significant between AFP, β-hCG (P>0.05). CONCLUSION Fluorine-18-FDG PET/CT was superior to CT in evaluation of therapy response, active disease in residual tissue and normal size lymph nodes, as well as when CT was negative and tumor markers were elevated. Elevated lactate dehydrogenase (LDH) contributes to positive 18F-FDG PET/CT findings.
{"title":"18F-FDG PET/CT value in the detection of seminoma and correlation with CT and tumor marker levels - up to 8 years of follow-up.","authors":"J. Petrović, S. Beatovic, D. Šobić-Šaranović, S. Odalović, M. Stojiljković, I. Grozdić-Milojević, Miloš Veljković, Darko Jovanović, V. Artiko","doi":"10.1967/s002449912432","DOIUrl":"https://doi.org/10.1967/s002449912432","url":null,"abstract":"OBJECTIVE\u0000Positron emission tomography/computed tomography using fluorine-18 fluoro-deoxyglucose (18F-FDG PET/CT) is not routinely used for diagnosis of testicular carcinoma. Unlike CT which cannot confirm with certainty the nature of the lesions, especially in post-therapy setting, 18F-FDG PET/CT detects active disease by showing increased glucose metabolism within the lesions.\u0000\u0000\u0000AIM\u0000Determination of 18F-FDG PET/CT usefulness in detection of seminoma, therapy response evaluation and comparison to CT findings and tumor marker levels.\u0000\u0000\u0000MATERIAL AND METHODS\u0000Eighty-two men (age 39.8±10.1) after orchiectomy and histopathological confirmation of seminoma were included in this study. Indications for 18F-FDG PET/CT were initial staging, restaging after chemo/radiotherapy with positive/uncertain CT, suspected recurrence on CT, elevated tumor markers. All patients had clinical follow-up of up to 8 years (median 33.5) after the first 18F-FDG PET/CT examination. Degree of metabolic activity was analyzed visually and semi-quantitatively using maximum standardized uptake value(SUVmax).\u0000\u0000\u0000RESULTS\u0000Fluorine-18-FDG PET/CT was true positive in 36 patients (43.9%) with average SUVmax of 7.9±4.8.Recurrence was mostly found in retroperitoneal lymph nodes and distant metastases in lungs, bones, liver. Six findings were false positive and 3 false negative. Sensitivity, specificity, accuracy of 18F-FDG PET/CT were 92.3%, 86.0%, 89.0% and of CT 60.8%, 66.6%, 63.4%. Pearson Chi-square test showed statistically significant difference between the results of 18F-FDG PET/CT and CT (P=0.016). Significant correlation was found between positive 18F-FDG PET/CT findings and levels of LDH (P=0.043), while non-significant between AFP, β-hCG (P>0.05).\u0000\u0000\u0000CONCLUSION\u0000Fluorine-18-FDG PET/CT was superior to CT in evaluation of therapy response, active disease in residual tissue and normal size lymph nodes, as well as when CT was negative and tumor markers were elevated. Elevated lactate dehydrogenase (LDH) contributes to positive 18F-FDG PET/CT findings.","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2022-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44580102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Xue Liu, Qi Wang, Baoshuai Zhang, Tao Jiang, W. Zeng
OBJECTIVE We performed a systematic review and meta-analysis to evaluate the application value of fluorine-18-prostate specific membrane antigen (18F-PSMA-1007) positron emission tomography/computed tomography (PET/CT) in patients with different serum prostate specific antigen (PSA) levels and primary prostate cancer (PCa) or the biochemical recurrence of PCa. METHODS A comprehensive electronic literature search of the PubMed, Embase and Cochrane Library databases was conducted in accordance with the PRISMA statement. We calculated the pooled sensitivity and specificity of 18F-PSMA-1007 PET/CT in PCa. A summary receiver operator characteristic (SROC) curve and the area under the curve (AUC) were used to assess the accuracy of 18F-PSMA-1007 PET/CT for PCa. RESULTS The final analysis included 11 studies that described 799 patients and 4261 lesions with 18F-PSMA-1007 PET/CT in PCa. The pooled sensitivity and specificity of 18F-PSMA-1007 PET/CT in PCa were 0.836 and 0.946, respectively. The per-patient pooled sensitivity and specificity of 18F-PSMA-1007 PET/CT in PCa were 0.934 and 0.453, and the per-lesion values were 0.816 and 0.979, respectively. The pooled sensitivity and specificity of 18F-PSMA-1007 PET/CT in PCa with PSA>2ng/mL were 0.923 and 0.442 in a patient-based analysis and 0.799 and 0.961 in a lesion-based analysis, respectively. The pooled sensitivity and specificity of 18F-PSMA-1007 PET/CT in PCa with PSA≤2ng/mL were 0.832 and 0.277 in a patient-based analysis, respectively. CONCLUSION This meta-analysis showed that 18F-PSMA-1007 PET/CT has a higher diagnostic value for prostate cancer in the setting of primary PCa and biochemical recurrence. As serum PSA levels increase, the diagnostic accuracy of 18F-PSMA-1007 PET/CT also improves.
{"title":"Diagnostic accuracy of 18F-PSMA-1007 PET/CT for prostate cancer in primary staging and biochemical recurrence with different serum PSA levels: A systematic review and meta-analysis.","authors":"Xue Liu, Qi Wang, Baoshuai Zhang, Tao Jiang, W. Zeng","doi":"10.1967/s002449912438","DOIUrl":"https://doi.org/10.1967/s002449912438","url":null,"abstract":"OBJECTIVE\u0000We performed a systematic review and meta-analysis to evaluate the application value of fluorine-18-prostate specific membrane antigen (18F-PSMA-1007) positron emission tomography/computed tomography (PET/CT) in patients with different serum prostate specific antigen (PSA) levels and primary prostate cancer (PCa) or the biochemical recurrence of PCa.\u0000\u0000\u0000METHODS\u0000A comprehensive electronic literature search of the PubMed, Embase and Cochrane Library databases was conducted in accordance with the PRISMA statement. We calculated the pooled sensitivity and specificity of 18F-PSMA-1007 PET/CT in PCa. A summary receiver operator characteristic (SROC) curve and the area under the curve (AUC) were used to assess the accuracy of 18F-PSMA-1007 PET/CT for PCa.\u0000\u0000\u0000RESULTS\u0000The final analysis included 11 studies that described 799 patients and 4261 lesions with 18F-PSMA-1007 PET/CT in PCa. The pooled sensitivity and specificity of 18F-PSMA-1007 PET/CT in PCa were 0.836 and 0.946, respectively. The per-patient pooled sensitivity and specificity of 18F-PSMA-1007 PET/CT in PCa were 0.934 and 0.453, and the per-lesion values were 0.816 and 0.979, respectively. The pooled sensitivity and specificity of 18F-PSMA-1007 PET/CT in PCa with PSA>2ng/mL were 0.923 and 0.442 in a patient-based analysis and 0.799 and 0.961 in a lesion-based analysis, respectively. The pooled sensitivity and specificity of 18F-PSMA-1007 PET/CT in PCa with PSA≤2ng/mL were 0.832 and 0.277 in a patient-based analysis, respectively.\u0000\u0000\u0000CONCLUSION\u0000This meta-analysis showed that 18F-PSMA-1007 PET/CT has a higher diagnostic value for prostate cancer in the setting of primary PCa and biochemical recurrence. As serum PSA levels increase, the diagnostic accuracy of 18F-PSMA-1007 PET/CT also improves.","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":"1 1","pages":""},"PeriodicalIF":1.5,"publicationDate":"2022-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42599389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
D. Mamouli, S. Stavrakaki, I. Iakovou, D. Parisis, D. Karacostas, E. Papanastasiou, P. Ioannidis
OBJECTIVE We aimed to examine if single photon emission computed tomography (SPECT) can discriminate between variants of frontotemporal dementia (FTD). As a secondary investigation we identify and establish the linguistic differences between those variants. MATERIALS AND METHODS Nine patients with semantic variant primary progressive aphasia (svPPA), 8 with non-fluent variant primary progressive aphasia (nfvPPA) and 17 with behavioral variant of frontotemporal dementia (bvFTD) were compared on Addenbrooke's cognitive examination-revised (ACE-R), auditory comprehension, oral expression and verbal fluency. All patients were also compared with healthy controls. Patients were evaluated using technetium-99m-hexamethylproyleneamine oxime (99mTc-HMPAO) brain SPECT as a measure of regional cerebral flow. RESULTS Significant group differences between all patients and controls were found for ACE-R, auditory comprehension and oral expression. Semantic variant primary progressive aphasia patients performed higher in letter compared to category fluency with significant deficits in auditory comprehension and oral expression. Non-fluent variant primary progressive aphasia patients showed significant deficits in auditory comprehension but not oral expression while performed lightly worse in letter fluency compared to category. Behavioral variant of frontotemporal dementia patients showed deficits in auditory comprehension and oral expression and performed similar in category and letter fluency. Single photon emission computed tomography analysis revealed left frontotemporal hypoperfusion extending to the right frontotemporal region in svPPA patients. Non-fluent variant primary progressive aphasia patients presented left frontotemporal hypoperfusion with participation of the left parietal and right frontotemporal regions. Behavioral variant of frontotemporal dementia patients showed bilateral frontotemporal hypoperfusion compared to parietal and visual cortices. CONCLUSION Our findings suggest that SPECT may assist in the discrimination of the FTD variants. We also confirmed that bvFTD patients share similar language deficits with svPPA patients.
{"title":"SPECT analysis and language profile in Greek speaking patients with subtypes of frontotemporal dementia.","authors":"D. Mamouli, S. Stavrakaki, I. Iakovou, D. Parisis, D. Karacostas, E. Papanastasiou, P. Ioannidis","doi":"10.1967/s002449912436","DOIUrl":"https://doi.org/10.1967/s002449912436","url":null,"abstract":"OBJECTIVE\u0000We aimed to examine if single photon emission computed tomography (SPECT) can discriminate between variants of frontotemporal dementia (FTD). As a secondary investigation we identify and establish the linguistic differences between those variants.\u0000\u0000\u0000MATERIALS AND METHODS\u0000Nine patients with semantic variant primary progressive aphasia (svPPA), 8 with non-fluent variant primary progressive aphasia (nfvPPA) and 17 with behavioral variant of frontotemporal dementia (bvFTD) were compared on Addenbrooke's cognitive examination-revised (ACE-R), auditory comprehension, oral expression and verbal fluency. All patients were also compared with healthy controls. Patients were evaluated using technetium-99m-hexamethylproyleneamine oxime (99mTc-HMPAO) brain SPECT as a measure of regional cerebral flow.\u0000\u0000\u0000RESULTS\u0000Significant group differences between all patients and controls were found for ACE-R, auditory comprehension and oral expression. Semantic variant primary progressive aphasia patients performed higher in letter compared to category fluency with significant deficits in auditory comprehension and oral expression. Non-fluent variant primary progressive aphasia patients showed significant deficits in auditory comprehension but not oral expression while performed lightly worse in letter fluency compared to category. Behavioral variant of frontotemporal dementia patients showed deficits in auditory comprehension and oral expression and performed similar in category and letter fluency. Single photon emission computed tomography analysis revealed left frontotemporal hypoperfusion extending to the right frontotemporal region in svPPA patients. Non-fluent variant primary progressive aphasia patients presented left frontotemporal hypoperfusion with participation of the left parietal and right frontotemporal regions. Behavioral variant of frontotemporal dementia patients showed bilateral frontotemporal hypoperfusion compared to parietal and visual cortices.\u0000\u0000\u0000CONCLUSION\u0000Our findings suggest that SPECT may assist in the discrimination of the FTD variants. We also confirmed that bvFTD patients share similar language deficits with svPPA patients.","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2022-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44764708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
OBJECTIVE The aim of this retrospective study was to evaluate the relationship between human epidermal growth factor receptor 2 (HER2) expression and fluorine-18-fluorodeoxyglucose (18F-FDG) uptake in positron emission tomography with computed tomography (PET/CT) in gastric carcinoma. MATERIALS AND METHODS Gastric carcinoma patients who had 18F-FDG PET/CT scans before treatment were enrolled in this study. Ninety PET/CT images were evaluated before resection or neoadjuvant treatment of 69 patients with gastric carcinoma who had HER2 examination tests. The maximum standardized uptake value (SUVmax) at early (SUV1) and delayed images (SUV2) if any were calculated. In addition, liver SUVmax was measured from the normal liver parenchyma at the dual time (SUV1 liver and SUV2 liver). Tumor-to-liver SUVmax ratio (TLR), retention indexes (RI) from SUVmax, and TLR values obtained from dual-time images were calculated. RESULTS Histological type of 69 patients were 85.5% adenocarcinoma, 10.1% signet ring cell carcinoma, 2.9% adenosquamous carcinoma, 1.4% mucinous adenocarcinomas. Human epidermal growth factor receptor 2 negative group included 56 (81.2%) patients and the positive group had 10 (14.35%) patients. We did not find any statistical difference for the values of SUVmax and tumor-to-liver SUVmax on all histological types of gastric carcinoma on the dual-phase PET scan. High-level SUV1 was found in the HER2 positive group (8.01±3.11) than negative group (6.15±3.76) in early PET/CT imaging (P=0.043) for adenocarcinoma patients. A positive correlation was observed between HER2 and SUV1 in adenocarcinoma patients (r=0.254,P=0.042). An inverse correlation was determined for histological grade with SUV1 (r=-0.29,P=0.048), TLR1 (r=-0.29,P=0.048) and TLR2 (r=-0.324, P=0.03). CONCLUSION Patients with HER2 expression in gastric adenocarcinomas had higher SUVmax values, but no significant difference was found between the groups when the tumor/liver ratio was measured by SUVmax from normal liver parenchyma when background activity was excluded. Signet ring cell carcinoma type and the presence of the signet ring component had no effect on 18F-FDG uptake.
{"title":"The relationship between HER2 expression and 18F-FDG in gastric carcinoma.","authors":"Aynur Ozen, G. Tatar","doi":"10.1967/s002449912430","DOIUrl":"https://doi.org/10.1967/s002449912430","url":null,"abstract":"OBJECTIVE\u0000The aim of this retrospective study was to evaluate the relationship between human epidermal growth factor receptor 2 (HER2) expression and fluorine-18-fluorodeoxyglucose (18F-FDG) uptake in positron emission tomography with computed tomography (PET/CT) in gastric carcinoma.\u0000\u0000\u0000MATERIALS AND METHODS\u0000Gastric carcinoma patients who had 18F-FDG PET/CT scans before treatment were enrolled in this study. Ninety PET/CT images were evaluated before resection or neoadjuvant treatment of 69 patients with gastric carcinoma who had HER2 examination tests. The maximum standardized uptake value (SUVmax) at early (SUV1) and delayed images (SUV2) if any were calculated. In addition, liver SUVmax was measured from the normal liver parenchyma at the dual time (SUV1 liver and SUV2 liver). Tumor-to-liver SUVmax ratio (TLR), retention indexes (RI) from SUVmax, and TLR values obtained from dual-time images were calculated.\u0000\u0000\u0000RESULTS\u0000Histological type of 69 patients were 85.5% adenocarcinoma, 10.1% signet ring cell carcinoma, 2.9% adenosquamous carcinoma, 1.4% mucinous adenocarcinomas. Human epidermal growth factor receptor 2 negative group included 56 (81.2%) patients and the positive group had 10 (14.35%) patients. We did not find any statistical difference for the values of SUVmax and tumor-to-liver SUVmax on all histological types of gastric carcinoma on the dual-phase PET scan. High-level SUV1 was found in the HER2 positive group (8.01±3.11) than negative group (6.15±3.76) in early PET/CT imaging (P=0.043) for adenocarcinoma patients. A positive correlation was observed between HER2 and SUV1 in adenocarcinoma patients (r=0.254,P=0.042). An inverse correlation was determined for histological grade with SUV1 (r=-0.29,P=0.048), TLR1 (r=-0.29,P=0.048) and TLR2 (r=-0.324, P=0.03).\u0000\u0000\u0000CONCLUSION\u0000Patients with HER2 expression in gastric adenocarcinomas had higher SUVmax values, but no significant difference was found between the groups when the tumor/liver ratio was measured by SUVmax from normal liver parenchyma when background activity was excluded. Signet ring cell carcinoma type and the presence of the signet ring component had no effect on 18F-FDG uptake.","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2022-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46169618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
OBJECTIVE To investigate the correlation among the maximum standardized uptake value (SUVmax) on fluorine-18-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) and tumor differentiation, size, and Ki67 in patients with moderately and poorly differentiate dintrahepatic cholangiocarcinoma (ICC). MATERIALS AND METHODS The 18F-FDG PET/CT imaging data of 116 patients with single ICC lesions confirmed by pathology were retrospectively evaluated. Pathological characteristics of the tumor such as the largest tumor diameter, differentiation, Ki67 expression, SUVmax of the primary tumor, and the tumor to normal background ratio (TNR) were recorded. RESULTS Among the 116 lesions, 45, 51, and 20 lesions were classified into the moderately differentiated, moderately-poorly, and poorly differentiated groups, respectively. There were significant differences in the SUVmax (P=0.033) and TNR (P=0.044) among the three groups. Maximum SUV was significantly correlated with differentiation (r=0.244, P=0.008). When the cases were categorized according to the tumor size (group 1, ≤3cm, n=14; group 2, >3 and ≤5 cm, n=37; group 3, >5 and ≤10 cm, n=52; group 4, >10 cm, n=13), there were significant differences in the SUVmax (P<0.001) and TNR (P<0.001) among the four groups. Maximum SUV was significantly correlated with tumor size (r=0.481, P<0.001). Among the 116 lesions, 38 lesions and 78 lesions were classified into the low Ki67 and high Ki67 expression groups, respectively. There were significant differences in the SUVmax (P=0.028) and TNR (P=0.007) between the two groups. Maximum SUV was significantly correlated with Ki67 expression (r=0.242, P=0.009). CONCLUSION In moderately and poorly differentiated ICC, the SUVmax and TNR are significantly associated with tumor differentiation, size, and Ki67 expression.
目的探讨中、低分化双肝胆管癌(ICC)患者氟-18-氟脱氧葡萄糖(18F-FDG)正电子发射断层扫描/计算机断层扫描(PET/CT)最大标准化摄取值(SUVmax)与肿瘤分化、大小、Ki67的相关性。材料与方法回顾性分析116例经病理证实的单发ICC病变的18F-FDG PET/CT影像资料。记录肿瘤的病理特征，如最大肿瘤直径、分化、Ki67表达、原发肿瘤SUVmax、肿瘤与正常背景比(TNR)等。结果116例病变中，中分化组45例，中分化组51例，低分化组20例。三组间SUVmax (P=0.033)、TNR (P=0.044)差异均有统计学意义。最大SUV与分化显著相关(r=0.244, P=0.008)。按肿瘤大小分组(1组≤3cm, n=14;第2组，bbb3≤5 cm, n=37;第3组，bbb5≤10 cm, n=52;组4，>10 cm, n=13)， 4组间SUVmax (P<0.001)、TNR (P<0.001)差异均有统计学意义。最大SUV与肿瘤大小显著相关(r=0.481, P<0.001)。116个病变中，Ki67低表达组38个，Ki67高表达组78个。两组患者的SUVmax (P=0.028)和TNR (P=0.007)差异有统计学意义。最大SUV与Ki67表达显著相关(r=0.242, P=0.009)。结论在中、低分化ICC中，SUVmax和TNR与肿瘤分化、大小和Ki67表达有显著相关性。
{"title":"Correlation among maximum standardized 18F-FDG uptake and pathological differentiation, tumor size, and Ki67 in patients with moderately and poorly differentiated intrahepatic cholangiocarcinoma.","authors":"Yi-qiu Zhang, Bei-lei Li, Yibo He, Lifang Pang, Hao-jun Yu, Hongcheng Shi","doi":"10.1967/s002449912435","DOIUrl":"https://doi.org/10.1967/s002449912435","url":null,"abstract":"OBJECTIVE\u0000To investigate the correlation among the maximum standardized uptake value (SUVmax) on fluorine-18-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) and tumor differentiation, size, and Ki67 in patients with moderately and poorly differentiate dintrahepatic cholangiocarcinoma (ICC).\u0000\u0000\u0000MATERIALS AND METHODS\u0000The 18F-FDG PET/CT imaging data of 116 patients with single ICC lesions confirmed by pathology were retrospectively evaluated. Pathological characteristics of the tumor such as the largest tumor diameter, differentiation, Ki67 expression, SUVmax of the primary tumor, and the tumor to normal background ratio (TNR) were recorded.\u0000\u0000\u0000RESULTS\u0000Among the 116 lesions, 45, 51, and 20 lesions were classified into the moderately differentiated, moderately-poorly, and poorly differentiated groups, respectively. There were significant differences in the SUVmax (P=0.033) and TNR (P=0.044) among the three groups. Maximum SUV was significantly correlated with differentiation (r=0.244, P=0.008). When the cases were categorized according to the tumor size (group 1, ≤3cm, n=14; group 2, >3 and ≤5 cm, n=37; group 3, >5 and ≤10 cm, n=52; group 4, >10 cm, n=13), there were significant differences in the SUVmax (P<0.001) and TNR (P<0.001) among the four groups. Maximum SUV was significantly correlated with tumor size (r=0.481, P<0.001). Among the 116 lesions, 38 lesions and 78 lesions were classified into the low Ki67 and high Ki67 expression groups, respectively. There were significant differences in the SUVmax (P=0.028) and TNR (P=0.007) between the two groups. Maximum SUV was significantly correlated with Ki67 expression (r=0.242, P=0.009).\u0000\u0000\u0000CONCLUSION\u0000In moderately and poorly differentiated ICC, the SUVmax and TNR are significantly associated with tumor differentiation, size, and Ki67 expression.","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2022-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48621056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：